QQQ $ 605.30 $ 0.00 (0 %)
DIA $ 464.47 $ 0.00 (0 %)
SPY $ 667.55 $ 0.00 (0 %)
TLT $ 90.95 $ 0.00 (0 %)
GLD $ 390.05 $ 0.00 (0 %)
$ 0.1975
-- x --
-- x --
-- - --
$ 0.05 - $ 0.28
115,930
na
na
$ 1.44
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-biora-therapeutics-bior-stock-is-down-45

Biora Therapeutics shares are trading lower by 45% during Tuesday's session. The company announced that it will be delisted...

 hc-wainwright--co-maintains-buy-on-biora-therapeutics-adjusts-price-target-to-23-1-10-reverse-stock-split

HC Wainwright & Co. analyst Joseph Pantginis maintains Biora Therapeutics (NASDAQ:BIOR) with a Buy, adjusts target to $23 f...

 biora-therapeutics-q3-eps-504-misses-385-estimate-sales-3200k-down-from-31800k-yoy

Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(5.04) per share which missed the analyst consensus estimate of ...

 biora-therapeutics-announces-3m-registered-direct-offering--for-the-purchase-and-sale-of-745342-shares-of-common-stock-at-an-offering-price-of-4025-per-share-of-common-stock-priced-at-the-market-under-nasdaq-rules

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that it has enter...

 biora-therapeutics-achieves-iso-13485-certification-demonstrating-the-cos-commitment-to-compliance-with-the-most-rigorous-global-regulatory-and-quality-standards

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it has been award...

 hc-wainwright--co-reiterates-buy-on-biora-therapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 pr...

 biora-therapeutics-q2-2024-gaap-eps-004-beats-045-estimate-sales-318000k-up-from-2000k-yoy

Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION